Solvonis Therapeutics plc

SVNS

GB00BMD1Z199

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:25 2025-02-12 EST			5-day change	1st Jan Change
0.1850 ^GBX	0.00%		-9.76%	-9.76%

01-21	Solvonis Therapeutics plc Provides Update on FDA Pre-IND Meeting for Awakn Life Sciences' Drug Candidate AWKN-002	CI
01-15	Graft Polymer (UK) Plc will Change its Ticker to SVNS from GPL	CI

Graft Polymer (UK) Plc will Change its Name to Solvonis Therapeutics plc

January 15, 2025 at 12:00 am

Effective January 15, 2025, Graft Polymer (UK) Plc will change its name to Solvonis Therapeutics plc.

Latest news about Solvonis Therapeutics plc

Solvonis Therapeutics plc Provides Update on FDA Pre-IND Meeting for Awakn Life Sciences' Drug Candidate AWKN-002	01-21	CI
Graft Polymer (UK) Plc will Change its Ticker to SVNS from GPL	01-15	CI
Graft Polymer (UK) Plc will Change its Name to Solvonis Therapeutics plc	01-15	CI
Graft Polymer (UK) Rebrands to Solvonis Therapeutics	01-14	MT
Graft Polymer (UK) to Buy Peer Awakn Life Sciences	12-16	MT
Awakn Life Sciences Corp. signed a letter of intent to acquire Graft Polymer (UK) Plc for CAD 9 million in a reverse merger transaction.	12-15	CI
Strategic Minerals touts improved Cobre sales	24-10-15	AN
Graft Polymer (UK) Partner Secures Research Deal for Potential Trauma-related Disorder Treatment	24-10-15	MT
Graft Polymer selects Eurfins to test aminoindane series	24-10-04	AN
Graft Polymer Enlists Eurofins Discovery to Test Co-lead Aminoindane Series	24-10-04	MT
Britain's Graft Polymer Appoints New Chair	24-09-26	MT
Graft Polymer (Uk) plc Announces Board Changes	24-09-26	CI
Graft Polymer confident as biotech firm as loss narrows	24-09-13	AN
Graft Polymer (UK) Plc Reports Earnings Results for the Half Year Ended June 30, 2024	24-09-13	CI
Graft Polymer makes Awakn progress; ORIT Sweden deal	24-08-28	AN
Graft Polymer's Partner Awakn Identifies Key Compounds to Develop PTSD Treatment	24-08-28	MT
Graft Polymer (UK) plc and Awakn Life Sciences Corp. Provide Collaboration Progress Update	24-08-28	CI
Graft Polymer CFO Steps Down	24-08-12	MT
EXECUTIVE CHANGES: New chief executives at Cornish Metals and ValiRx	24-08-12	AN
Graft Polymer (UK) Plc Announces Resignation of Yifat Steuer from Its Board of Directors	24-08-12	CI
Graft Polymer (UK) Plc Announces Resignation of Yifat Steuer as Chief Financial Officer	24-08-12	CI
Graft Polymer's Chief Technology Officer Steps Down	24-08-01	MT
Graft Polymer (UK) Plc Announces the Resignation of Victor Bolduev from Its Board of Directors and as Chief Technology Officer	24-08-01	CI
Graft Polymer, Awakn to Jointly Develop New Therapies for Mental Health Disorders	24-07-18	MT
Awakn Life Sciences Corp. Announces Collaboration Agreement with Graft Polymer (UK) Plc	24-07-18	CI

Chart Solvonis Therapeutics plc

Duration

Period

SVNS: Dynamic Chart

Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC, is a United Kingdom-based biotechnology company. The Company is focused on developing intellectual property related to the treatment of mental health and substance-use disorders, and co-developing therapeutics for these conditions. It focuses on improving outcomes for individuals suffering from these disorders, with an initial focus on trauma-related mental health conditions, such as PTSD. PTSD is a debilitating mental health condition characterized by persistent and distressing symptoms following exposure to traumatic events.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-06-24 - Q4 2024 Earnings Release (Projected)

More about the company